According to Genocea Biosciences 's latest financial reports the company's current earnings are HK$1.91 Million. In 2021 the company made an earning of -HK$0.27 Billion, an increase over its 2020 earnings that were of -HK$0.35 Billion. The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2022 (TTM) | -HK$0.3 Billion | 11.45% |
2021 | -HK$0.27 Billion | -24.06% |
2020 | -HK$0.35 Billion | 12.23% |
2019 | -HK$0.31 Billion | 40.05% |
2018 | -HK$0.22 Billion | -50.96% |
2017 | -HK$0.45 Billion | 14.4% |
2016 | -HK$0.39 Billion | 16.69% |
2015 | -HK$0.34 Billion | 20.36% |
2014 | -HK$0.28 Billion | 69.64% |
2013 | -HK$0.17 Billion |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
![]() Agenus
AGEN | -HK$0.74 Billion | 153.37% | ๐บ๐ธ USA |
![]() Novavax NVAX | HK$4.00 B | -1,471.85% | ๐บ๐ธ USA |
![]() Merck MRK | HK$168.36 B | -57,775.24% | ๐บ๐ธ USA |
![]() iBio IBIO | -HK$0.13 Billion | -56.36% | ๐บ๐ธ USA |
![]() Pfizer PFE | HK$81.16 B | -27,905.11% | ๐บ๐ธ USA |